PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Cash & equivalents declining -31.05% while TRVN's grows 1.26%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Below half of TRVN's 10.30%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Current Assets Growth compared to TRVN's zero value, indicating worse performance.
-31.37%
Below half of TRVN's 5.86%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
76.50%
Below half TRVN's -1.33%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of TRVN's -3.20%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Below half of TRVN's 5.23%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-21.72%
Less than half of TRVN's 41.22%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
1.25-1.5x TRVN's -16.25%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
1.1-1.25x TRVN's -18.33%. Bill Ackman questions if the firm is incurring more total obligations than competitor.
0.01%
Less than half of TRVN's 10.81%. David Dodd sees fewer share issuances vs. competitor.
-3.53%
≥ 1.5x TRVN's -1.19%. David Dodd sees higher yoy retained profits than competitor.
-5.52%
Higher AOCI Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
Below half TRVN's 25.71%. Michael Burry sees potential underperformance in building shareholder capital.
-30.47%
Below half TRVN's 5.23%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
Less than half of TRVN's -511.02%. David Dodd sees better deleveraging or stronger cash buildup than competitor.